• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Clinical Outcomes

Is Statin Use Associated with Better COVID-19 Hospitalization Outcomes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Statins may be able to mitigate myocardial injury and thrombotic events due to anti-inflammatory and antithrombotic properties
  • Gupta et al. (Nature Communications, 2021) investigated the hypothesis that statins may mitigate adverse COVID-19 consequences

METHODS:

  • Retrospective cohort study (between February 1st and May 12th, 2020)
  • Participants
    • Hospitalized with COVID-19
  • Exposures
    • Antecedent statin use
  • Study design
    • Data derived from electronic medical record
    • A multivariable logistic regression model was used to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications
  • Primary outcome
    • In-hospital mortality within 30 days
  • Secondary outcome
    • Invasive mechanical ventilation within 30 days of admission

RESULTS:

  • 2626 total patients patients
    • Antecedent statin users: 36.2%
  • 1296 patients ascertained for 1:1 propensity-score matching
    • 648 statin users | 648 non-statin users
  • In the propensity-matched cohort, statin use was significantly associated with lower odds of in-hospital mortality within 30 days
    • Occurrence in statin users: 14.8%
    • Occurrence in non-statin users: 26.5%
    • Odds ratio 0.47 (95% CI, 0.36 to 0.62; p < 0.001)
  • Patients on statins had
    • Lower WBC count at presentation: 7.6 vs 8.1; p < 0.01   
    • Lower CRP levels: 100.0 vs 120.7; p < 0.01
  • No significant differences for the following additional outcomes
    • Invasive mechanical ventilation | Vasopressor use | Renal replacement therapy | Length of stay between the groups

CONCLUSION:

  • Antecedent statin use among patients hospitalized for COVID-19 is associated with a reduction in in-hospital mortality
  • The authors conclude

In this large analysis from a quaternary academic medical institution in an epicenter of the COVID-19 pandemic, we demonstrated that antecedent statin use was associated with significantly lower rates of in-hospital mortality within 30 days

These results indicate the important need for randomized controlled trials evaluating the benefits of statin therapy in patients affected by COVID-19

Learn More – Primary Sources:

Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Clinical Outcomes Posts
Next >

Related ObG Topics:

Are ACE Inhibitors and ARBs Associated with Increased COVID-19 Susceptibility?
What are the Strongest Predictors of COVID-19 Hospitalization and Critical Illness?
CDC Weekly Update: Which Comorbidities are Associated with COVID-19 in the US?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site